跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

SANOFI PASTEUR S.A.

首页临床试验发起方与机构SANOFI PASTEUR S.A.

SANOFI PASTEUR S.A.

Cuyo 3532, Martínez, Buenos Aires, 阿根廷

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

9

6 进行中

药物批准

16

批准总数

监管机构

1

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

不适用

3

33.3%

试验状态分布

进行中（未招募）

6

66.7%

已完成

3

33.3%

相关临床试验

该机构主办的试验（9）

Immunogenicity Study of the Antibody Persistence and Booster Effect of the DTaP-IPV-Hep B-PRP-T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series of DTaP-IPV-Hep B-PRP-T or Infanrix hexa™ Administered at 2, 4, and 6 Months of Age in Healthy Mexican Infants

进行中（未招募）

Apr 20121190 名受试者

ot-to-Lot Consistency Study of DTaP-IPV-Hep B-PRP-T Vaccine Administered at 2-4-6 Months of Age in Healthy Mexican Infants

进行中（未招募）

Apr 20121190 名受试者

Immunogenicity Study of a DTaP-IPV-Hep B-PRP-T Combined Vaccine in Comparison to Infanrix hexa™, Both Concomitantly Administered with Prevnar™ at 2, 4, and 6 Months of Age in Thai Infants

进行中（未招募）

Apr 2012412 名受试者

Evaluation of Antibody Persistence Following a Primary Series at 2, 4, and 6 Months on Trial A3L24 and Booster Effect of the DTaP-IPV-Hep B-PRP-T Combined Vaccine or Infanrix hexa® Concomitantly Administered with Prevenar® at 12 to 24 Months of Age in Healthy Latin American Infants

进行中（未招募）

Apr 20121376 名受试者

Immunogenicity Study of DTaP-IPV-Hep B-PRP-T Combined Vaccine in Comparison to Infanrix hexa™, at 2-4-6 Months of Age in Healthy Peruvian Infants

进行中（未招募）

Apr 2012266 名受试者

ot-to-Lot Consistency Study of DTaP-IPV-Hep B-PRP-T Vaccine Administered at 2-4-6 Months of Age in Healthy Latin American Infants Concomitantly with Prevenar™ and Rotarix™

进行中（未招募）

Apr 20121376 名受试者

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants

第 1 页，共 2 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

16

药物批准

近期批准

Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine and Haemophilus type b conjugate vaccine, adsorbed

Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine and Haemophilus type b conjugate vaccine, adsorbed

Inactivated Hepatitis A vaccine, adsorbed

POLIOMYELITIS VACCINE(INACTIVATED)

Inactivated Hepatitis A vaccine, adsorbed

Group A and Group C Meningococcal Polysaccharide Vaccine

Inactivated Hepatitis A vaccine, adsorbed

Group A and Group C Meningococcal Polysaccharide Vaccine

Group A and Group C Meningococcal Polysaccharide Vaccine

Group A and Group C Meningococcal Polysaccharide Vaccine

资讯

暂无资讯文章

本页目录

概览
相关临床试验9
药物批准16
资讯

返回机构列表